AROVYNTM (tulathromycin injection) is now available to veterinarians who prescribe tulathromycin to control and treat bovine respiratory disease (BRD), as well as treat footrot and pink eye. The FDA-approved prescription antibiotic is the latest addition to Merck Animal Health’s comprehensive antimicrobial portfolio and BRD solutions.
“AROVYN provides veterinarians and producers with a new, cost-effective option for tulathromycin,” said Merck Animal Health technical services manager David Sjeklocha, D.V.M. “AROVYN, which is approved for use in high-risk cattle, can also be used to treat BRD, foot rot, and pinkeye – all of which are common and costly diseases.”
AROVYN is indicated in beef and non-lactating dairy cattle for the treatment of BRD and the control of respiratory disease in animals at high risk of developing BRD caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis. It is also approved for the treatment of the pink eye or infectious bovine keratoconjunctivitis (IBK) caused by Moraxella bovis, as well as foot rot caused by Fusobacterium necrophorum and Porphyromonas levii. AROVYN is indicated in suckling calves, dairy calves, and veal calves for the treatment of BRD caused by M. haemolytica, P. multocida, H. somni, and M. bovis.
AROVYN is approved for cattle and swine and is available in vials of 50, 100, 250, and 500 mL. It is produced in the same facility as other Merck Animal Health antimicrobials, such as ZUPREVO® (tildipirosin), and adheres to the same stringent quality control standards.
For more information, visit www.ArovynforBRD.com or your veterinarian.
